Armata Pharmaceuticals, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual filing; the supplied filing text does not provide standalone fourth-quarter results.
Business context
Armata is a clinical-stage biotechnology company developing natural and engineered bacteriophage therapies for antibiotic-resistant and difficult-to-treat bacterial infections. Its lead programs target Pseudomonas aeruginosa (AP-PA02) and Staphylococcus aureus (AP-SA02). It has no approved products or product-sales revenue.
Financial results and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Grant revenue | $0.823 million | None |
| Research and development expense | $14.444 million | $9.824 million |
| General and administrative expense | $7.966 million | $9.265 million |
| Loss from operations | $(21.587) million | $(19.752) million |
| Net loss | $(22.181) million | $(19.479) million |
| Basic and diluted loss per share | $(1.35) | Basic $(2.49); diluted $(2.55) |
| Net cash used in operating activities | $(18.270) million | $(15.582) million |
- R&D expense rose $4.6 million, principally reflecting clinical-trial and laboratory supplies and increased headcount. G&A expense fell $1.3 million, partly due to lower share-based compensation and merger-related costs in 2019.
- Loss from operations widened by $1.8 million and net loss by $2.7 million. Lower loss per share primarily reflects a substantially higher weighted-average share count, not improved net income.
- At year-end, cash and cash equivalents were $9.649 million; restricted cash was $1.2 million. Working capital was $4.141 million, total assets $39.516 million, total liabilities $20.659 million, and stockholders’ equity $18.857 million.
- Financing activities provided $23.210 million in 2020, mainly from the $25 million gross 2020 Innoviva placement (about $22.9 million net proceeds) and a $0.717 million PPP loan. Investing activities used $0.824 million, mainly for property and equipment.
- The filing reports no conventional funded term debt, but includes the PPP loan and substantial lease obligations: $12.428 million present value of operating lease liabilities at year-end. It also reports $1.940 million of current deferred asset-acquisition consideration.
- The company reported recurring losses and negative operating cash flows, and the auditor highlighted substantial doubt about its ability to continue as a going concern. Management said year-end resources plus the subsequent $20 million gross 2021 placement were expected to fund planned operations into the first quarter of 2022; management did not consider the financing plan sufficient to remove the going-concern uncertainty.
Material developments and outlook
- FDA allowed the AP-PA02 IND to proceed on October 14, 2020. The planned Phase 1b/2a SWARM-P.a. trial evaluates inhaled AP-PA02 in cystic fibrosis patients with chronic pulmonary P. aeruginosa infection; topline multiple-dose data were anticipated in 2022.
- Armata received a Cystic Fibrosis Foundation award of up to $5 million for AP-PA02; $1 million was received in 2020 and recorded as a reduction of R&D expense. Further payments depend on milestones.
- A $15 million Department of Defense/MTEC award is intended to partially fund an AP-SA02 Phase 1b/2 study for complicated S. aureus bacteremia. Funding is cost-reimbursable; $0.823 million of grant revenue was recognized in 2020 as eligible costs were incurred. The company planned to file an IND and begin the study in 2021, subject to development and enrollment conditions.
- In January and March 2021, Innoviva completed a further private placement for approximately $20 million gross, issuing shares and warrants with a $3.25 exercise price. The filing says Innoviva held approximately 59.6% of outstanding shares after the transaction; warrant exercise could increase its ownership and voting influence. The placement is subsequent to FY2020 and is not included in year-end cash.
- COVID-19 delayed trial-site identification and initiation and caused some supply delays, including materials potentially in high demand for vaccine manufacturing. Management could not estimate the pandemic’s effects on 2021 or 2022 operations, liquidity, or trial progress.
- Armata expects continued significant operating losses and requires additional financing beyond the stated runway. No product-revenue, earnings, or margin guidance is provided. The Merck research collaboration targets undisclosed infectious disease agents; no milestones or revenue had been earned under the agreement as of year-end.
Risks, contingencies, and unusual items
- The phage approach is novel, and no bacteriophage product had received regulatory approval. Early, preclinical, and expanded-access results may not predict controlled clinical-trial outcomes; regulatory, manufacturing, and enrollment delays could increase costs or prevent approval.
- COVID-19 creates risks to enrollment, site operations, suppliers, and development timelines. Failure to raise capital could force Armata to defer or reduce programs, relinquish rights, or cease operations.
- The $0.717 million PPP loan bears 1% interest and may not be forgiven; repayment is required for any unforgiven balance. The filing says management anticipated forgiveness but could not assure it.
- The $10.256 million in-process R&D asset relates to the S. aureus program. No impairment was recorded, but its valuation depends on assumptions including clinical success probabilities, trial and approval timing, and forecast sales. The auditor identified this valuation as a critical audit matter.
- Innoviva’s large ownership stake and warrants may dilute other shareholders and give Innoviva substantial influence over stockholder matters. The company also disclosed material potential warrant and equity-plan dilution.
- The filing reports no material legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not audit internal control effectiveness.
Important facts for investors to verify
- Whether AP-PA02 and AP-SA02 trials met enrollment, safety, and timing milestones, and whether the stated 2022 data expectation remains achievable.
- Current cash, burn rate, financing needs, and whether subsequent financing or grants have extended the runway beyond the first quarter of 2022.
- How much of the MTEC and CFF awards has been received, the conditions for remaining payments, and any related future royalty, fee, or repayment obligations.
- PPP loan forgiveness status and the effect of lease payments and other commitments on liquidity.
- Innoviva’s current ownership and voting position, outstanding warrants, and potential dilution from exercise or future equity issuance.
- The filing contains inconsistent figures for the 2021 placement’s second-tranche shares: one section reports 4,286,935, while another reports 4,285,935. Verify the definitive transaction and share count in subsequent filings.
- Whether clinical, regulatory, or commercial developments require revisiting the assumptions underlying the $10.256 million IPR&D valuation.